UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

_________________________

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 15, 2015 (May 12, 2015)

 

_________________________

 

 

VBI VACCINES INC.

(Exact name of registrant as specified in charter)

 

 

 

Delaware

 

000-18188

 

93-0589534

(State or other jurisdiction of

incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

222 3rd Street, Suite 2241

Cambridge, Massachusetts 02142

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (617) 830-3031

 

 

 (Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below).

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

[  ] Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17 CFR 240.13(e)-4(c))

 

 
 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

On May 12, 2015, VBI Vaccines Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders.  At the meeting, the stockholders voted to: (1) elect seven directors; (2) approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation; (3) approve, on advisory basis, the compensation of our named executive officers; and (4) the ratification of the appointment of Peterson Sullivan LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015. The voting results on these proposals were as follows:

 

Proposal 1: Election of Seven Directors

 

Director

Votes For

Withheld

Broker Non-Votes

Jeff R. Baxter FCMA

14,545,514

  19,403

1,272,348

Sam Chawla

14,545,864

  19,053

1,272,348

Trent D. Davis

14,385,665

179,262

1,272,348

Michel De Wilde, Ph.D.

14,564,337

      580

1,272,348

Steven Gillis Ph.D.

14,564,337

      580

1,272,348

Michael Steinmetz Ph.D.

14,546,124

  18,793

1,272,348

Alan P. Timmins

14,564,337

      580

1,272,348


Proposal 2: Approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation

 

1 year

2 years

3 years

Abstentions

Broker Non-Votes

14,556,181

702

480

7,554

1,272,348

 

Proposal 3: Approve, on advisory basis, the compensation of our named executive officers

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

14,550,557

8,080

6,280

1,272,348

 

Proposal 4: Ratification of the appointment of Peterson Sullivan LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015

 

Votes For

Votes Against

Abstentions

15,834,330

2,935

0

 

 
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  

VBI VACCINES INC.

  

 

 

 

 

 

 

  

  

  

  

Date: May 15, 2015

By:

/s/ Jeff Baxter

  

 

 

Jeff Baxter

Chief Executive Officer